-transparent.png){kind=logo}
Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group. 1993
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
Hämatologisch-Onkologische Praxis Altona, Hamburg, Germany.
The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective remissions were seen. Four patients (3 women and 1 man; 9%) experienced 3-6 months' disease stabilization. The toxicity of the drug, given at a dose of 240 mg daily, was negligible. Because of the minimal side-effects, Toremifene may be recommended for patients who have only a small number of slowly growing metastases, in particular to soft tissue and lung.
Related Publications
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
January 1995,
British journal of cancer,
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
August 1997,
European journal of cancer (Oxford, England : 1990),
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
September 1988,
Cancer,
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
September 1992,
Melanoma research,
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
January 1992,
European journal of cancer (Oxford, England : 1990),
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
January 1990,
European journal of cancer (Oxford, England : 1990),
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
January 1992,
European journal of cancer (Oxford, England : 1990),
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
August 1982,
European journal of cancer & clinical oncology,
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
April 1993,
American journal of clinical oncology,
U R Kleeberg, and
E Engel, and
E B Bröcker, and
F Avril, and
P Israels, and
J Weiss, and
L Kangas, and
M van Glabbeke, and
M A Lentz
January 1989,
Acta oncologica (Stockholm, Sweden),
